fluoxetine has been researched along with Recrudescence in 141 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The AFFINITY trial (Assessment of Fluoxetine in Stroke Recovery) reported that oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and seizures." | 9.41 | Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration. ( Almeida, OP; Anderson, CS; Billot, L; Dennis, MS; Etherton-Beer, C; Flicker, L; Ford, AH; Gommans, J; Hackett, ML; Hankey, GJ; Jan, S; Lundström, E; Lung, T; Mead, GE; Sunnerhagen, KS; Thang-Nguyen, H; Yi, Q, 2021) |
| "To evaluate the effect of fluoxetine on three-year recurrence rate of acute ischemic stroke." | 9.27 | Effect of fluoxetine on three-year recurrence in acute ischemic stroke: A randomized controlled clinical study. ( Cai, Z; Chang, X; Chen, S; Guo, Y; He, Y; Liang, Y; Tang, B; Zeng, S, 2018) |
| " Fluoxetine is effective against anxiety and panic disorders, while its use has shown promising results for VVS." | 9.24 | Fluoxetine vs. placebo for the treatment of recurrent vasovagal syncope with anxiety sensitivity. ( Flevari, P; Katsaras, D; Katsimardos, A; Leftheriotis, D; Lekakis, J; Repasos, E, 2017) |
| "In the present study, we assessed the relationship between serum folate, vitamin B12, and homocysteine levels on the rate of relapse in outpatients with remitted major depressive disorder (MDD) during a 28-week continuation phase of treatment with fluoxetine." | 9.11 | Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. ( Alpert, JE; Bottiglieri, T; Fava, M; Green, CH; Mischoulon, D; Nierenberg, AA; Papakostas, GI; Petersen, T; Rosenbaum, JF, 2004) |
| "The efficacy of fluoxetine in the acute management of bulimia nervosa is well established; however, few controlled studies have examined whether continuation of pharmacotherapy provides protection from relapse." | 9.10 | A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. ( Halmi, KA; Koke, SC; Lee, JS; Romano, SJ; Sarkar, NP, 2002) |
| " The safety and effectiveness of a new formulation of enteric-coated fluoxetine (90 mg) given once weekly was tested during the continuation treatment of major depressive disorder." | 9.09 | The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. ( Fava, M; Judge, R; Robinson, JM; Schmidt, ME, 2000) |
| "The median frequency of binge eating in the previous 28 days declined from 22 to four episodes in the fluoxetine group but increased from 15 to 18 episodes in the placebo group." | 9.09 | Fluoxetine for bulimia nervosa following poor response to psychotherapy. ( Agras, WS; Chally, MK; Devlin, MJ; Fairburn, CG; Kahn, C; Walsh, BT; Wilson, GT, 2000) |
| "To assess the safety and efficacy of continued fluoxetine treatment following successful acute therapy of panic disorder." | 9.09 | Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. ( Lydiard, RB; Michelson, D; Pollack, M; Tamura, R; Tepner, R; Tollefson, G, 1999) |
| "In this article, we report two cases of pustular psoriasis flaring up after fluoxetine administration." | 8.85 | Flare-up of pustular psoriasis with fluoxetine: possibility of a serotoninergic influence? ( Alli, N; Gur, G; Polat, M; Tamer, E, 2009) |
| "Efficiency of fluoxetine (one of the selective serotonin reuptake inhibitors) was examined in the course of treatment of 24 patients with atypical depressions that were characterized by prevalence of either negative (12 patients) or positive (12 patients) affectivity." | 7.70 | [Effectiveness of fluoxetine (portal) in atypical depressions]. ( Andriushchenko, AV, 1998) |
| "The authors present a case report of neuroleptic malignant syndrome (NMS) in a patient commencing treatment with fluoxetine alone who had previously been treated with several antipsychotic and antidepressant combinations." | 7.68 | Fluoxetine and neuroleptic malignant syndrome. ( Goldbloom, DS; Halman, M, 1990) |
| "The AFFINITY trial (Assessment of Fluoxetine in Stroke Recovery) reported that oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and seizures." | 5.41 | Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration. ( Almeida, OP; Anderson, CS; Billot, L; Dennis, MS; Etherton-Beer, C; Flicker, L; Ford, AH; Gommans, J; Hackett, ML; Hankey, GJ; Jan, S; Lundström, E; Lung, T; Mead, GE; Sunnerhagen, KS; Thang-Nguyen, H; Yi, Q, 2021) |
| "Following weight restoration in an acute care setting, 93 women with anorexia nervosa were randomly assigned to receive fluoxetine or placebo and were discharged to outpatient care, where they also received cognitive-behavioral therapy for up to 1 year." | 5.41 | Time Course of Relapse Following Acute Treatment for Anorexia Nervosa. ( Attia, E; Kaplan, AS; Walsh, BT; Wang, Y; Xu, T, 2021) |
| " Eligible participants are those who: are between the ages of 18 and 74 years; have had at least two episodes of depression; and have been taking antidepressants for 9 months or more and are currently taking citalopram 20 mg, sertraline 100 mg, fluoxetine 20 mg or mirtazapine 30 mg but are well enough to consider stopping their medication." | 5.30 | A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRes ( Bacon, F; Clarke, CS; Donkor, Y; Duffy, L; Freemantle, N; Gilbody, S; Hunter, R; Kendrick, T; Kessler, D; King, M; Lanham, P; Lewis, G; Mangin, D; Marston, L; Moore, M; Nazareth, I; Wiles, N, 2019) |
| "To evaluate the effect of fluoxetine on three-year recurrence rate of acute ischemic stroke." | 5.27 | Effect of fluoxetine on three-year recurrence in acute ischemic stroke: A randomized controlled clinical study. ( Cai, Z; Chang, X; Chen, S; Guo, Y; He, Y; Liang, Y; Tang, B; Zeng, S, 2018) |
| " Fluoxetine is effective against anxiety and panic disorders, while its use has shown promising results for VVS." | 5.24 | Fluoxetine vs. placebo for the treatment of recurrent vasovagal syncope with anxiety sensitivity. ( Flevari, P; Katsaras, D; Katsimardos, A; Leftheriotis, D; Lekakis, J; Repasos, E, 2017) |
| "To compare fluoxetine 20 to 60 mg/day with placebo for prevention of relapse of major depressive disorder in children and adolescents who had achieved Children's Depression Rating Scale, Revised scores of < or =28 during treatment with fluoxetine 20 to 60 mg." | 5.11 | Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. ( Emslie, GJ; Findling, RL; Heiligenstein, JH; Hoog, SL; Jacobson, JG; McCracken, JT; Nilsson, ME; Wagner, KD, 2004) |
| "A quasi-experimental secondary analysis of data collected from a randomized placebo-controlled trial of fluoxetine (60 mg or 30 mg) versus placebo for smoking cessation." | 5.11 | Experimenter-defined quit dates for smoking cessation: adherence improves outcomes for women but not for men. ( Borrelli, B; Hitsman, B; Niaura, R; Papandonatos, G; Spring, B, 2004) |
| "In the present study, we assessed the relationship between serum folate, vitamin B12, and homocysteine levels on the rate of relapse in outpatients with remitted major depressive disorder (MDD) during a 28-week continuation phase of treatment with fluoxetine." | 5.11 | Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. ( Alpert, JE; Bottiglieri, T; Fava, M; Green, CH; Mischoulon, D; Nierenberg, AA; Papakostas, GI; Petersen, T; Rosenbaum, JF, 2004) |
| "The efficacy of fluoxetine in the acute management of bulimia nervosa is well established; however, few controlled studies have examined whether continuation of pharmacotherapy provides protection from relapse." | 5.10 | A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. ( Halmi, KA; Koke, SC; Lee, JS; Romano, SJ; Sarkar, NP, 2002) |
| " The authors of this study investigated predictors of relapse among 989 participants (60% women) in a randomized, double-blind, 10-week multicenter trial to determine the effect of fluoxetine (30 or 60 mg) versus placebo in combination with behavioral counseling for smoking cessation." | 5.09 | Influences of gender and weight gain on short-term relapse to smoking in a cessation trial. ( Borrelli, B; Hitsman, B; Niaura, R; Papandonatos, G; Spring, B, 2001) |
| " The safety and effectiveness of a new formulation of enteric-coated fluoxetine (90 mg) given once weekly was tested during the continuation treatment of major depressive disorder." | 5.09 | The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. ( Fava, M; Judge, R; Robinson, JM; Schmidt, ME, 2000) |
| "The median frequency of binge eating in the previous 28 days declined from 22 to four episodes in the fluoxetine group but increased from 15 to 18 episodes in the placebo group." | 5.09 | Fluoxetine for bulimia nervosa following poor response to psychotherapy. ( Agras, WS; Chally, MK; Devlin, MJ; Fairburn, CG; Kahn, C; Walsh, BT; Wilson, GT, 2000) |
| "To assess the safety and efficacy of continued fluoxetine treatment following successful acute therapy of panic disorder." | 5.09 | Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. ( Lydiard, RB; Michelson, D; Pollack, M; Tamura, R; Tepner, R; Tollefson, G, 1999) |
| "Fluoxetine's effect (30 mg, 60 mg, and placebo) on postcessation weight gain was studied among participants from a randomized, double-blind 10-week smoking cessation trial who met strict criteria for abstinence and drug levels." | 5.09 | Weight suppression and weight rebound in ex-smokers treated with fluoxetine. ( Borrelli, B; Keuthen, NJ; Kristeller, J; Niaura, R; Ockene, JK; Spring, B, 1999) |
| "A group of 23 elderly outpatients with dysthymic disorder participated in a 13-week fluoxetine trial." | 5.08 | Fluoxetine discontinuation in elderly dysthymic patients. ( Devanand, DP; Kim, MK; Nobler, MS, 1997) |
| "The objective was to present naturalistic 1-year follow-up information of 96 child and adolescent outpatients with major depressive disorder who had been randomized in an 8-week double-blind, placebo-controlled trial of fluoxetine." | 5.08 | Fluoxetine in child and adolescent depression: acute and maintenance treatment. ( Carmody, T; Emslie, GJ; Kowatch, RA; Mayes, TL; Rush, AJ; Weinberg, WA, 1998) |
| "In this article, we report two cases of pustular psoriasis flaring up after fluoxetine administration." | 4.85 | Flare-up of pustular psoriasis with fluoxetine: possibility of a serotoninergic influence? ( Alli, N; Gur, G; Polat, M; Tamer, E, 2009) |
| "Convincing evidence from placebo-referenced randomized controlled trials supports efficacy for clomipramine and selective serotonin reuptake inhibitors for acute treatment of obsessive-compulsive disorder." | 4.84 | Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder. ( Fineberg, NA; Ipser, J; Pallanti, S; Pampaloni, I; Stein, DJ, 2007) |
| "Anxiety disorders alone did not predict response or remission, but the total number of co-morbid illnesses was associated with remission in depressed children and adolescents treated with fluoxetine." | 3.76 | Anxiety as a predictor of treatment outcome in children and adolescents with depression. ( Cheung, A; Emslie, G; Kiss, A; Levitt, A; Mayes, T; Michalak, E; Schaffer, A, 2010) |
| "(1) When an antidepressant is considered a necessary addition to psychological support in treating patients with depression, the first-line drug is a tricyclic such as clomipramine or a selective serotonin reuptake inhibitor (SSRI) such as paroxetine; (2) Agomelatine, a melatonin receptor agonist, is approved in the European Union for the treatment of depression; (3) Available evaluation does not include any clinical trials designed to compare the efficacy of agomelatine with that of a tricyclic or a selective serotonin reuptake inhibitor." | 3.75 | Agomelatine: new drug. Adverse effects and no proven efficacy. ( , 2009) |
| "Efficiency of fluoxetine (one of the selective serotonin reuptake inhibitors) was examined in the course of treatment of 24 patients with atypical depressions that were characterized by prevalence of either negative (12 patients) or positive (12 patients) affectivity." | 3.70 | [Effectiveness of fluoxetine (portal) in atypical depressions]. ( Andriushchenko, AV, 1998) |
| "The authors present a case report of neuroleptic malignant syndrome (NMS) in a patient commencing treatment with fluoxetine alone who had previously been treated with several antipsychotic and antidepressant combinations." | 3.68 | Fluoxetine and neuroleptic malignant syndrome. ( Goldbloom, DS; Halman, M, 1990) |
| "The Staged Treatment in Early Psychosis (STEP) sequential multiple assignment randomized trial took place within the clinical program at Orygen, Melbourne, Australia." | 3.30 | A Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at Ultrahigh Risk of Psychosis: The Staged Treatment in Early Psychosis (STEP) Sequential Multiple Assignment Randomized Trial. ( Amminger, GP; Baird, S; Buccilli, K; Carter, C; Dempsey, SA; Dixon, L; Ferguson, N; Formica, M; Kerr, M; Krcmar, M; Loewy, R; McGorry, PD; Mebrahtu, Y; Mei, C; Nelson, B; Niendam, TA; Polari, A; Quinn, AL; Ruslins, A; Shumway, M; Spark, J; Street, R; Wallis, N; Wannan, C; Yuen, HP, 2023) |
| "Adults with major depressive disorder (MDD) often experience reduced quality of life (QOL)." | 3.01 | Quality of life after response to acute-phase cognitive therapy for recurrent depression. ( Jarrett, RB; Jha, MK; Minhajuddin, A; Thase, ME; Vittengl, JR, 2021) |
| "To prevent recurrence (i." | 2.82 | Quantifying and qualifying the preventive effects of acute-phase cognitive therapy: Pathways to personalizing care. ( Clark, LA; Jarrett, RB; Minhajuddin, A; Thase, ME; Vittengl, JR, 2016) |
| "Youth (aged 8-17 years) with major depressive disorder (MDD) were treated with fluoxetine for 6 weeks." | 2.80 | Continued Effectiveness of Relapse Prevention Cognitive-Behavioral Therapy Following Fluoxetine Treatment in Youth With Major Depressive Disorder. ( Emslie, GJ; Foxwell, AA; Jones, JM; Kennard, BD; King, J; Mayes, TL; Moore, J; Nakonezny, PA, 2015) |
| "After patients with major depressive disorder (MDD) respond to acute-phase cognitive therapy (CT), continuation-phase treatments may be applied to improve long-term outcomes." | 2.80 | Predictors of longitudinal outcomes after unstable response to acute-phase cognitive therapy for major depressive disorder. ( Clark, LA; Jarrett, RB; Thase, ME; Vittengl, JR, 2015) |
| "Sex predicted recurrence (57." | 2.76 | Recovery and recurrence following treatment for adolescent major depression. ( Albano, AM; Becker-Weidman, E; Burns, B; Curry, J; Emslie, G; Feeny, N; Ginsburg, G; Jacobs, R; Kastelic, E; Kennard, B; Kirchner, J; Kratochvil, C; Lavanier, S; March, J; May, D; Mayes, T; Reinecke, M; Rohde, P; Silva, S; Simons, A; Walkup, J; Weller, E; Wells, K, 2011) |
| "Many patients with major depressive disorder (MDD) who achieve full remission after antidepressant treatment still have residual depressive symptoms." | 2.76 | Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. ( Baer, L; Clain, A; Iovieno, N; Nierenberg, AA; van Nieuwenhuizen, A, 2011) |
| "All patients met DSM-IV criteria for major depressive disorder and scored a minimum of 18 on the 24-item Hamilton Rating Scale for Depression (HAM-D) at baseline." | 2.71 | Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder. ( Belmaker, RH; Bersudsky, Y; Nemets, B, 2005) |
| "Patients with major depressive disorder remain at risk for relapse following remission and often continue to experience subthreshold symptoms." | 2.70 | Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. ( Alpert, JE; Buchin, J; Fava, M; Matthews, JD; Nierenberg, AA; Pava, J; Perlis, RH; Sickinger, AH, 2002) |
| " Discontinuation for lack of efficacy was lower in BP II (5%) than in UP (12%) patients (p = not significant [NS]), whereas dropouts for adverse events were similar in BP II (11%) and UP (9%) patients." | 2.69 | Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. ( Amsterdam, JD; Beasley, C; Fawcett, J; Garcia-España, F; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Schweizer, E, 1998) |
| "Relapse was defined as a 50% increase in HDRS with total < or = 17." | 2.69 | Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. ( Charney, DS; Delgado, PL; Heninger, GR; Krystal, JH; Licinio, J; Miller, HL; Moreno, FA; Salomon, RM, 1999) |
| "fluoxetine treatment induced a long-lasting increase in alcohol consumption during relapse, an effect that was not observed in the case of bupropion treatment." | 1.51 | Bupropion, a possible antidepressant without negative effects on alcohol relapse. ( Alen, F; Antón, M; Arco, R; Ballesta, A; de Fonseca, FR; de Heras, RG; Nogueira-Arjona, R; Orio, L; Pavón, FJ; Ramírez-López, M; Romero-Sanchiz, P; Serrano, A; Suárez, J; Vargas, A, 2019) |
| "Overall, the number of at least moderately severe adverse events decreased with time." | 1.33 | What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? ( Albert, A; De Bruyckere, K; Demyttenaere, K; Dewé, W; Mesters, P; Sangeleer, M, 2005) |
| "The rapid recurrence of symptoms further supports the view of premenstrual dysphoric disorder as a clinical entity distinct from depression." | 1.32 | Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment. ( Brown, EB; Joliat, MJ; Miner, CM; Pearlstein, T, 2003) |
| "Using a model of repeated trauma in rats, we observed significant spatial memory impairment together with significantly increased 5HT(1A) receptor density (B(max)), decreased 5HT(1A) receptor affinity (K(d)), and significantly increased 5HT(2A) receptor affinity on day 7 poststress." | 1.32 | Serotonin and stress: protective or malevolent actions in the biobehavioral response to repeated trauma? ( Brand, L; Harvey, BH; Naciti, C; Stein, DJ, 2004) |
| " Seventeen patients with RBD according to DSM-IV and ICD-10 diagnostic criteria, who had no history of major depression were treated with a dosage of 20-40 mg fluoxetine daily." | 1.31 | Fluoxetine treatment in patients with recurrent brief depression. ( Aschauer, HN; Blasbichier, T; Brandstätter, N; Kasper, S; Pezawas, L; Riederer, F; Stamenkovic, M, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.42) | 18.7374 |
| 1990's | 57 (40.43) | 18.2507 |
| 2000's | 40 (28.37) | 29.6817 |
| 2010's | 33 (23.40) | 24.3611 |
| 2020's | 9 (6.38) | 2.80 |
| Authors | Studies |
|---|---|
| Pintori, N | 1 |
| Piva, A | 1 |
| Guardiani, V | 1 |
| Marzo, CM | 1 |
| Decimo, I | 1 |
| Chiamulera, C | 1 |
| McGorry, PD | 1 |
| Mei, C | 1 |
| Amminger, GP | 1 |
| Yuen, HP | 1 |
| Kerr, M | 1 |
| Spark, J | 1 |
| Wallis, N | 1 |
| Polari, A | 1 |
| Baird, S | 1 |
| Buccilli, K | 1 |
| Dempsey, SA | 1 |
| Ferguson, N | 1 |
| Formica, M | 1 |
| Krcmar, M | 1 |
| Quinn, AL | 1 |
| Mebrahtu, Y | 1 |
| Ruslins, A | 1 |
| Street, R | 1 |
| Wannan, C | 1 |
| Dixon, L | 1 |
| Carter, C | 1 |
| Loewy, R | 1 |
| Niendam, TA | 1 |
| Shumway, M | 1 |
| Nelson, B | 1 |
| Boland, EM | 1 |
| Vittengl, JR | 13 |
| Clark, LA | 10 |
| Thase, ME | 13 |
| Jarrett, RB | 13 |
| Tatay-Manteiga, A | 1 |
| Stutzman, S | 1 |
| Atluru, A | 1 |
| Jha, MK | 1 |
| Minhajuddin, A | 2 |
| Hankey, GJ | 1 |
| Hackett, ML | 1 |
| Almeida, OP | 1 |
| Flicker, L | 1 |
| Mead, GE | 1 |
| Dennis, MS | 1 |
| Etherton-Beer, C | 1 |
| Ford, AH | 1 |
| Billot, L | 1 |
| Jan, S | 1 |
| Lung, T | 1 |
| Lundström, E | 1 |
| Sunnerhagen, KS | 1 |
| Anderson, CS | 1 |
| Thang-Nguyen, H | 1 |
| Gommans, J | 1 |
| Yi, Q | 1 |
| Walsh, BT | 2 |
| Xu, T | 1 |
| Wang, Y | 1 |
| Attia, E | 1 |
| Kaplan, AS | 1 |
| Anna Clark, L | 1 |
| He, Y | 1 |
| Cai, Z | 1 |
| Zeng, S | 1 |
| Chen, S | 1 |
| Tang, B | 1 |
| Liang, Y | 1 |
| Chang, X | 1 |
| Guo, Y | 1 |
| Smits, JAJ | 1 |
| Ballesta, A | 2 |
| Orio, L | 1 |
| Arco, R | 2 |
| Vargas, A | 1 |
| Romero-Sanchiz, P | 1 |
| Nogueira-Arjona, R | 1 |
| de Heras, RG | 1 |
| Antón, M | 1 |
| Ramírez-López, M | 1 |
| Serrano, A | 1 |
| Pavón, FJ | 1 |
| de Fonseca, FR | 1 |
| Suárez, J | 2 |
| Alen, F | 2 |
| Duffy, L | 1 |
| Bacon, F | 1 |
| Clarke, CS | 1 |
| Donkor, Y | 1 |
| Freemantle, N | 1 |
| Gilbody, S | 1 |
| Hunter, R | 1 |
| Kendrick, T | 1 |
| Kessler, D | 1 |
| King, M | 1 |
| Lanham, P | 1 |
| Lewis, G | 2 |
| Mangin, D | 1 |
| Marston, L | 1 |
| Moore, M | 1 |
| Nazareth, I | 1 |
| Wiles, N | 1 |
| Khom, S | 1 |
| Natividad, LA | 1 |
| Varodayan, FP | 1 |
| Patel, RR | 1 |
| Kirson, D | 1 |
| Bajo, M | 1 |
| Rubio, L | 1 |
| Martin-Fardon, R | 1 |
| Rodríguez de Fonseca, F | 1 |
| Roberto, M | 1 |
| Kornstein, SG | 2 |
| Pedersen, RD | 1 |
| Holland, PJ | 1 |
| Nemeroff, CB | 1 |
| Rothschild, AJ | 3 |
| Trivedi, MH | 1 |
| Ninan, PT | 2 |
| Keller, MB | 2 |
| Kennard, BD | 2 |
| Emslie, GJ | 5 |
| Mayes, TL | 3 |
| Nakonezny, PA | 2 |
| Jones, JM | 2 |
| Foxwell, AA | 2 |
| King, J | 2 |
| Rodriguez-Osorio, X | 1 |
| Fernandez-Pajarin, G | 1 |
| Arias-Rivas, S | 1 |
| Requena-Caballero, I | 1 |
| Lopez-Gonzalez, FJ | 1 |
| Arias, M | 1 |
| Peselow, ED | 1 |
| Tobia, G | 1 |
| Karamians, R | 1 |
| Pizano, D | 1 |
| IsHak, WW | 1 |
| Brown, GK | 1 |
| Borman, PD | 1 |
| Moore, J | 1 |
| Blázquez, A | 1 |
| Gassó, P | 1 |
| Mas, S | 1 |
| Plana, MT | 1 |
| Lafuente, A | 1 |
| Lázaro, L | 1 |
| Flevari, P | 2 |
| Leftheriotis, D | 2 |
| Repasos, E | 1 |
| Katsaras, D | 1 |
| Katsimardos, A | 1 |
| Lekakis, J | 1 |
| Gueorguieva, R | 1 |
| Chekroud, AM | 1 |
| Krystal, JH | 3 |
| Alves, ND | 1 |
| Correia, JS | 1 |
| Patrício, P | 1 |
| Mateus-Pinheiro, A | 1 |
| Machado-Santos, AR | 1 |
| Loureiro-Campos, E | 1 |
| Morais, M | 1 |
| Bessa, JM | 1 |
| Sousa, N | 1 |
| Pinto, L | 1 |
| Bot, ST | 1 |
| Tamer, E | 1 |
| Gur, G | 1 |
| Polat, M | 1 |
| Alli, N | 1 |
| Kocsis, JH | 2 |
| Ahmed, S | 1 |
| Thase, M | 1 |
| Friedman, ES | 1 |
| Dunlop, BW | 1 |
| Yan, B | 1 |
| Pedersen, R | 1 |
| Li, T | 1 |
| Keller, M | 1 |
| de Diego-Adeliño, J | 1 |
| Portella, MJ | 1 |
| Puigdemont, D | 1 |
| Pérez-Egea, R | 1 |
| Alvarez, E | 1 |
| Pérez, V | 1 |
| Gao, K | 1 |
| Kemp, DE | 1 |
| Ganocy, SJ | 1 |
| Muzina, DJ | 1 |
| Xia, G | 1 |
| Findling, RL | 2 |
| Calabrese, JR | 1 |
| Applebee, GA | 1 |
| Attarian, HP | 1 |
| Schenck, CH | 1 |
| Amsterdam, JD | 3 |
| Shults, J | 1 |
| Cheung, A | 1 |
| Mayes, T | 2 |
| Levitt, A | 1 |
| Schaffer, A | 1 |
| Michalak, E | 1 |
| Kiss, A | 1 |
| Emslie, G | 2 |
| Eppel, A | 1 |
| Curry, J | 1 |
| Silva, S | 1 |
| Rohde, P | 1 |
| Ginsburg, G | 1 |
| Kratochvil, C | 1 |
| Simons, A | 1 |
| Kirchner, J | 1 |
| May, D | 1 |
| Kennard, B | 1 |
| Feeny, N | 1 |
| Albano, AM | 1 |
| Lavanier, S | 1 |
| Reinecke, M | 1 |
| Jacobs, R | 1 |
| Becker-Weidman, E | 1 |
| Weller, E | 1 |
| Walkup, J | 1 |
| Kastelic, E | 1 |
| Burns, B | 1 |
| Wells, K | 1 |
| March, J | 1 |
| Iovieno, N | 1 |
| van Nieuwenhuizen, A | 1 |
| Clain, A | 1 |
| Baer, L | 2 |
| Nierenberg, AA | 5 |
| Ariturk, Z | 1 |
| Alici, H | 1 |
| Cakici, M | 1 |
| Davutoglu, V | 1 |
| Sah, A | 1 |
| Schmuckermair, C | 1 |
| Sartori, SB | 1 |
| Gaburro, S | 1 |
| Kandasamy, M | 1 |
| Irschick, R | 1 |
| Klimaschewski, L | 1 |
| Landgraf, R | 1 |
| Aigner, L | 1 |
| Singewald, N | 1 |
| Lin, HY | 1 |
| Lin, CC | 1 |
| Liu, CC | 1 |
| Raghunath, A | 1 |
| D'iakonov, AL | 1 |
| Lobanova, IV | 1 |
| Lê, AD | 1 |
| Harding, S | 1 |
| Juzytsch, W | 1 |
| Fletcher, PJ | 1 |
| Shaham, Y | 1 |
| Perlis, RH | 1 |
| Alpert, JE | 4 |
| Pava, J | 1 |
| Matthews, JD | 1 |
| Buchin, J | 1 |
| Sickinger, AH | 1 |
| Fava, M | 9 |
| Hendrick, V | 1 |
| Altshuler, L | 1 |
| Quitkin, FM | 4 |
| Petkova, E | 1 |
| McGrath, PJ | 2 |
| Taylor, B | 1 |
| Beasley, C | 3 |
| Stewart, J | 1 |
| Amsterdam, J | 2 |
| Rosenbaum, J | 2 |
| Reimherr, F | 2 |
| Fawcett, J | 4 |
| Chen, Y | 1 |
| Klein, D | 1 |
| Agell, I | 1 |
| Pearlstein, T | 1 |
| Joliat, MJ | 1 |
| Brown, EB | 1 |
| Miner, CM | 1 |
| Strik, JJ | 1 |
| van Praag, HM | 1 |
| Honig, A | 1 |
| Seymour, PM | 1 |
| Borrelli, B | 3 |
| Papandonatos, G | 2 |
| Spring, B | 3 |
| Hitsman, B | 2 |
| Niaura, R | 3 |
| Papakostas, GI | 2 |
| Petersen, T | 1 |
| Mischoulon, D | 1 |
| Green, CH | 1 |
| Bottiglieri, T | 1 |
| Rosenbaum, JF | 6 |
| Heiligenstein, JH | 1 |
| Hoog, SL | 1 |
| Wagner, KD | 1 |
| McCracken, JT | 1 |
| Nilsson, ME | 1 |
| Jacobson, JG | 1 |
| Harvey, BH | 1 |
| Naciti, C | 1 |
| Brand, L | 1 |
| Stein, DJ | 2 |
| Hart, BL | 1 |
| Cliff, KD | 1 |
| Tynes, VV | 1 |
| Bergman, L | 1 |
| Nemets, B | 1 |
| Bersudsky, Y | 1 |
| Belmaker, RH | 1 |
| Demyttenaere, K | 1 |
| Albert, A | 1 |
| Mesters, P | 1 |
| Dewé, W | 1 |
| De Bruyckere, K | 1 |
| Sangeleer, M | 1 |
| Theodorakis, GN | 1 |
| Livanis, EG | 1 |
| Karabela, G | 1 |
| Aggelopoulou, N | 1 |
| Kremastinos, DT | 1 |
| Epperson, CN | 1 |
| Amin, Z | 1 |
| Naftolin, F | 1 |
| Cappiello, A | 1 |
| Czarkowski, KA | 1 |
| Stiklus, S | 1 |
| Anderson, GM | 1 |
| Peterson, TJ | 1 |
| Feldman, G | 1 |
| Harley, R | 1 |
| Fresco, DM | 1 |
| Graves, L | 1 |
| Holmes, A | 1 |
| Bogdan, R | 1 |
| Bohn, L | 1 |
| Lury, RA | 1 |
| Segal, ZV | 1 |
| Fineberg, NA | 1 |
| Pampaloni, I | 1 |
| Pallanti, S | 1 |
| Ipser, J | 1 |
| Reinés, A | 1 |
| Cereseto, M | 1 |
| Ferrero, A | 1 |
| Sifonios, L | 1 |
| Podestá, MF | 1 |
| Wikinski, S | 1 |
| Lonnqvist, J | 1 |
| Sihvo, S | 1 |
| Syvälahti, E | 1 |
| Sintonen, H | 1 |
| Kiviruusu, O | 1 |
| Pitkanen, H | 1 |
| Mathews, J | 1 |
| Goldberg, JF | 1 |
| Sacks, MH | 1 |
| Hirschfeld, RM | 1 |
| Rappe, SM | 1 |
| Pava, JA | 2 |
| Kranzler, HR | 1 |
| Burleson, JA | 1 |
| Korner, P | 1 |
| Del Boca, FK | 1 |
| Bohn, MJ | 1 |
| Brown, J | 1 |
| Liebowitz, N | 1 |
| Altshuler, LL | 1 |
| Montgomery, DB | 1 |
| Roberts, A | 1 |
| Green, M | 1 |
| Bullock, T | 1 |
| Baldwin, D | 1 |
| Montgomery, SA | 1 |
| Maddocks, A | 1 |
| Grubb, BP | 1 |
| Samoil, D | 1 |
| Kosinski, D | 1 |
| Temesy-Armos, P | 1 |
| Akpunonu, B | 1 |
| Ricciardi, J | 1 |
| Keuthen, N | 1 |
| Pettit, AR | 1 |
| Buttolph, ML | 1 |
| Otto, M | 1 |
| Minichiello, W | 1 |
| Jenike, MA | 1 |
| Dufour, H | 1 |
| Katz, RJ | 1 |
| Rosenthal, M | 1 |
| Tollefson, GD | 1 |
| Stokes, PE | 1 |
| Kupfer, DJ | 3 |
| Terao, T | 1 |
| Browne, M | 1 |
| Horn, E | 1 |
| Jones, TT | 1 |
| Flint, AJ | 3 |
| Crosby, J | 1 |
| Genik, JL | 1 |
| Hambrecht, M | 1 |
| Javed, MA | 1 |
| Pezard, L | 1 |
| Nandrino, JL | 1 |
| Renault, B | 1 |
| el Massioui, F | 1 |
| Allilaire, JF | 1 |
| Müller, J | 1 |
| Varela, F | 1 |
| Martinerie, J | 1 |
| Clancy, K | 1 |
| Castañeda, R | 1 |
| Levy, R | 1 |
| Westreich, LM | 1 |
| Sussman, N | 1 |
| Iancu, I | 1 |
| Weizman, A | 1 |
| Kindler, S | 1 |
| Sasson, Y | 1 |
| Zohar, J | 1 |
| Rintelmann, JW | 1 |
| Rush, AJ | 2 |
| Varghese, T | 1 |
| Gullion, CM | 1 |
| Kowatch, RA | 2 |
| Hughes, CW | 1 |
| Rifat, SL | 2 |
| Panzer, PG | 1 |
| Fullilove, MT | 1 |
| Agosti, V | 2 |
| Stewart, JW | 2 |
| Devanand, DP | 1 |
| Kim, MK | 1 |
| Nobler, MS | 1 |
| Byrne, S | 1 |
| Lejoyeux, M | 1 |
| Adès, J | 1 |
| Corá-Locatelli, G | 1 |
| Greenberg, BD | 1 |
| Martin, JD | 1 |
| Murphy, DL | 1 |
| Roback, P | 1 |
| Vovin, RIa | 1 |
| Mazo, GE | 1 |
| Razorenova, TS | 1 |
| Razorenov, GI | 1 |
| Weinberg, WA | 1 |
| Carmody, T | 1 |
| Andriushchenko, AV | 1 |
| Garcia-España, F | 1 |
| Reimherr, FW | 2 |
| Schweizer, E | 1 |
| Kristeller, J | 1 |
| Ockene, JK | 1 |
| Keuthen, NJ | 1 |
| Delgado, PL | 1 |
| Miller, HL | 1 |
| Salomon, RM | 1 |
| Licinio, J | 1 |
| Moreno, FA | 1 |
| Heninger, GR | 1 |
| Charney, DS | 1 |
| Buysse, DJ | 1 |
| Cherry, C | 1 |
| Stapf, D | 1 |
| Frank, E | 2 |
| Michelson, D | 1 |
| Pollack, M | 1 |
| Lydiard, RB | 1 |
| Tamura, R | 2 |
| Tepner, R | 1 |
| Tollefson, G | 1 |
| Mathen, D | 1 |
| Marsden, CD | 1 |
| Bhatia, KP | 1 |
| Tzanakaki, M | 1 |
| Guazzelli, M | 1 |
| Nimatoudis, I | 1 |
| Zissis, NP | 1 |
| Smeraldi, E | 1 |
| Rizzo, F | 1 |
| Shear, MK | 1 |
| Rucci, P | 1 |
| Cyranowski, JM | 1 |
| Endicott, J | 1 |
| Fagiolini, A | 1 |
| Grochocinski, VJ | 1 |
| Houck, P | 1 |
| Maser, JD | 1 |
| Cassano, GB | 1 |
| Agras, WS | 1 |
| Devlin, MJ | 1 |
| Fairburn, CG | 1 |
| Wilson, GT | 1 |
| Kahn, C | 1 |
| Chally, MK | 1 |
| Schmidt, ME | 1 |
| Robinson, JM | 1 |
| Judge, R | 1 |
| Romano, S | 1 |
| Goodman, W | 1 |
| Gonzales, J | 1 |
| Grunhaus, L | 1 |
| Hirschman, S | 1 |
| Dolberg, OT | 1 |
| Schreiber, S | 1 |
| Dannon, PN | 1 |
| Stamenkovic, M | 1 |
| Blasbichier, T | 1 |
| Riederer, F | 1 |
| Pezawas, L | 1 |
| Brandstätter, N | 1 |
| Aschauer, HN | 1 |
| Kasper, S | 1 |
| Romano, SJ | 1 |
| Halmi, KA | 1 |
| Sarkar, NP | 1 |
| Koke, SC | 1 |
| Lee, JS | 1 |
| Tefferi, A | 1 |
| Fonseca, R | 1 |
| Brunswick, DJ | 1 |
| Beasley, CM | 2 |
| Seth, R | 1 |
| Jennings, AL | 1 |
| Bindman, J | 1 |
| Phillips, J | 1 |
| Bergmann, K | 1 |
| Brewerton, TD | 1 |
| Shannon, M | 1 |
| Gupta, S | 1 |
| Ghaly, N | 1 |
| Dewan, M | 1 |
| Selzer, JA | 1 |
| Oliveros, SC | 1 |
| Iruela, LM | 1 |
| Caballero, L | 1 |
| Baca, E | 1 |
| Reed, SM | 1 |
| Glick, JW | 1 |
| Fichtner, CG | 1 |
| Jobe, TH | 1 |
| Braun, BG | 1 |
| Burstein, A | 1 |
| Feder, R | 1 |
| Kerbeshian, J | 1 |
| Burd, L | 1 |
| Sayler, ME | 1 |
| Cunningham, GE | 1 |
| Weiss, AM | 1 |
| Masica, DN | 1 |
| Halman, M | 1 |
| Goldbloom, DS | 1 |
| Hon, D | 1 |
| Preskorn, SH | 1 |
| Linet, LS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Identifying Networks Underlying Compulsivity in Anorexia Nervosa for Targeting With Neuromodulation[NCT06138782] | 20 participants (Anticipated) | Interventional | 2023-10-16 | Recruiting | |||
| An Acute and Continuation Phase Study of the Comparative Efficacy Study of Venlafaxine ER (Effexor® XR) and Fluoxetine (Prozac®) in Achieving and Sustaining Remission (Wellness) in Patients With Recurrent Unipolar Major Depression; Followed by a Long Term[NCT00046020] | Phase 4 | 1,096 participants (Actual) | Interventional | 2000-08-31 | Completed | ||
| Pediatric MDD: Sequential Treatment With Fluoxetine and Relapse Prevention[NCT00612313] | 144 participants (Actual) | Interventional | 2008-02-29 | Completed | |||
| Prophylactic Cognitive Therapy for Depression.[NCT00118404] | Phase 3 | 523 participants (Actual) | Interventional | 2000-03-31 | Completed | ||
| Relapse Prevention of Bipolar Type-II Disorder[NCT00044616] | Phase 4 | 180 participants | Interventional | 2001-02-28 | Completed | ||
| Interaction of Estrogen and Serotonin in Modulating Brain Activation in Menopause[NCT01208324] | 47 participants (Actual) | Interventional | 2010-03-04 | Completed | |||
| Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial.[NCT00564564] | Phase 4 | 21 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| An Investigation of the Antidepressant Efficacy of a Dopamine Agonist With Neurotrophic Properties in Bipolar Disorder[NCT00025792] | Phase 2 | 200 participants | Interventional | 2001-10-31 | Completed | ||
| [NCT00113737] | 0 participants | Interventional | 1998-02-28 | Completed | |||
| [NCT00113711] | 0 participants | Interventional | 1995-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"K-Life interview was conducted at Weeks 6, 12, 18, 24, and 30, with ratings for depressive illness for each week throughout the study.~Ratings definitions: 1=Normal, no residual symptoms; 2=Presence of 1 or more symptosm in no more than mild degree; 3=Considerably less psychopathology than full criteria, but still obvious evidence of disorder with no more than moderate impairment; 4=Does not meet full criteria, but has major symptoms or impairment from the disorder; 5=Meets full criteria, but no extreme impairment; 6=Meets full criteria, and either has prominent psychotic symptoms or extreme impairment.~Time well is defined as each week the depression rating was a 1 or 2. Percent time well was defined as each week the depression rating was a 1 or 2 divided by the total number of weeks in the study.~Statistic: anova" (NCT00612313)
Timeframe: 30 weeks
| Intervention | Weeks spent well (Mean) |
|---|---|
| Continued Medication Alone | 12.8 |
| Continued Medication Plus CBT | 16.0 |
Remission is defined as CDRS-R <=28. Timing of remission is based on clinical assessment using the CDRS-R and K-Life to identify the week at which point the patient remitted. (NCT00612313)
Timeframe: 30 weeks
| Intervention | weeks (Mean) |
|---|---|
| Continued Medication Alone | 13.67 |
| Continued Medication Plus CBT | 11.33 |
"Relapse was defined as:~1) CDRS-R score >=40 with a history of 2 weeks of clinical deterioration or 2) CDRS-R<40, but with a 2 week history of significant clinical deterioration." (NCT00612313)
Timeframe: Measured at Weeks 12, 18, 24, and 30
| Intervention | probability of relapse (%) (Number) | |||
|---|---|---|---|---|
| Week 12 | Week 18 | Week 24 | Week 30 | |
| Continued Medication Alone | 3 | 10 | 20.5 | 26.5 |
| Continued Medication Plus CBT | 1 | 3.5 | 7 | 9 |
"Up through week 30, relapse was defined as:~1) CDRS-R score >=40 with a history of 2 weeks of clinical deterioration or 2) CDRS-R<40, but with a 2 week history of significant clinical deterioration.~From week 31-78, relapse was assessed using the K-Life. Relapse was defined as at least 2 weeks of a K-Life rating of 5 or 6; participants may also be identified as relapsing with a K-Life rating of 4 if the rating was for several weeks and not strictly related to stressful life events." (NCT00612313)
Timeframe: Weeks 52 and 78
| Intervention | Probability of Relapse (%) (Number) | |
|---|---|---|
| Week 52 | Week 78 | |
| Continued Medication Alone | 49 | 62 |
| Continued Medication Plus CBT | 27 | 36 |
Remission is defined as CDRS-R <=28 (up through week 30) or at least 8 consecutive weeks of a K-Life rating of 1 or 2. Timing of remission is based on clinical assessment using the CDRS-R and K-Life to identify the week at which point the patient remitted. (NCT00612313)
Timeframe: Weeks 52 and 78
| Intervention | Probability of remission (%) (Number) | |
|---|---|---|
| Week 52 | Week 78 | |
| Continued Medication Alone | 89 | 92 |
| Continued Medication Plus CBT | 94 | 96 |
Remission is defined as CDRS-R <=28. (NCT00612313)
Timeframe: Measured at Weeks 12, 18, 24, and 30
| Intervention | probability of remitting (%) (Number) | |||
|---|---|---|---|---|
| Week 12 | Week 18 | Week 24 | Week 30 | |
| Continued Medication Alone | 59 | 71 | 80 | 84 |
| Continued Medication Plus CBT | 68 | 79 | 86 | 90 |
"Longitudinal Interval Follow-up Evaluation - Psychiatric Status Rating (LIFE-PSR) of 5 or more (on a scale from 1 to 6 measuring major depressive disorder) for 2 consecutive weeks according to evaluator blinded to randomized assignment~LIFE-PSR Scale:~= No residual symptoms, no current evidence of the disorder.~= Mild symptoms~= Considerably less psychopathology than full criteria with no more than moderate impairment~= Does not meet full criteria but has major symptoms of impairment~= Meets criteria without extreme impairment in functioning~= Meets criteria with extreme impairment in functioning~The relapse rate was estimated using Kaplan-Meier estimates (Kaplan, Meier J Am Stat, 1958, pp.457-481)" (NCT00118404)
Timeframe: Measured at month 8
| Intervention | % patients who relapsed (Number) |
|---|---|
| Continuation Phase Fluoxetine | 18 |
| Continuation Phase Cognitive Therapy | 18.3 |
| Continuation Phase Pill Placebo | 32.7 |
"Longitudinal Interval Follow-up Evaluation - Psychiatric Status Rating (LIFE-PSR) of 5 or more (on a scale from 1 to 6 measuring MDD) for 2 consecutive weeks according to evaluator blinded to randomized assignment~LIFE-PSR Scale:~= No residual symptoms, no current evidence of the disorder.~= Mild symptoms~= Considerably less psychopathology than full criteria with no more than moderate impairment~= Does not meet full criteria but has major symptoms of impairment~= Meets criteria without extreme impairment in functioning~= Meets criteria with extreme impairment in functioning~Relapse/recurrence rate was estimated using Kaplan-Meier estimates (Kaplan, Meier J Am Stat, 1958, pp.457-481)." (NCT00118404)
Timeframe: Measured at month 32
| Intervention | % patients who relapsed/recurred (Number) |
|---|---|
| Continuation Phase Fluoxetine | 41.1 |
| Continuation Phase Cognitive Therapy | 45.2 |
| Continuation Phase Pill Placebo | 56.3 |
"Longitudinal Interval Follow-up Evaluation - Psychiatric Status Rating (LIFE-PSR) of 5 or more (on a scale from 1 to 6 measuring MDD) for 2 consecutive weeks according to evaluator blinded to randomized assignment~LIFE-PSR Scale:~= No residual symptoms, no current evidence of the disorder.~= Mild symptoms~= Considerably less psychopathology than full criteria with no more than moderate impairment~= Does not meet full criteria but has major symptoms of impairment~= Meets criteria without extreme impairment in functioning~= Meets criteria with extreme impairment in functioning~Relapse/recurrence rate was estimated using Kaplan-Meier estimates (Kaplan, Meier J Am Stat, 1958, pp.457-481)" (NCT00118404)
Timeframe: Measured at month 20
| Intervention | % patients who relapsed/recurred (Number) |
|---|---|
| Continuation Phase Fluoxetine | 35.1 |
| Continuation Phase Cognitive Therapy | 35.0 |
| Continuation Phase Pill Placebo | 42.7 |
To replicate and extend our previous behavioral findings of an interaction between estrogen therapy (ET) and tryptophan depletion on verbal memory in a group of early menopausal women randomized to receive ET. Blood-oxygen-level dependent or BOLD signal is the outcome of BOLD imaging, which is a technique used in functional MRI. BOLD signal reflects changes in regional cerebral blood flow which delineate regional activity. A positive BOLD signal marks an increase in regional blood flow, while a negative BOLD signal marks a decrease in regional blood flow. A positive percent change means that between scans the BOLD signal i.e. blood flow in that region has increased, a negative percent change means that the BOLD signal has decreased between scans. (NCT01208324)
Timeframe: 8 weeks
| Intervention | percentage of BOLD signal changes (Mean) |
|---|---|
| High Ace | -.43 |
| Low Ace | .20 |
10 reviews available for fluoxetine and Recrudescence
| Article | Year |
|---|---|
[Recurrence of encephalitis after 25 years due to anti-NMDA receptor antibodies].
Topics: Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Anticonvulsants; Autoantibodies; Autoantigens; Crit | 2014 |
Antenatal depression: guidelines for when to use pharmacotherapy.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression; Female; Fluoxetine; Humans; Inf | 2008 |
Flare-up of pustular psoriasis with fluoxetine: possibility of a serotoninergic influence?
Topics: Adult; Depressive Disorder; Dermatitis, Exfoliative; Drug Eruptions; Female; Fluoxetine; Follow-Up S | 2009 |
Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder.
Topics: Clomipramine; Fluoxetine; Humans; Meta-Analysis as Topic; Obsessive-Compulsive Disorder; Randomized | 2007 |
Guidelines for the long-term treatment of depression.
Topics: Adult; Amitriptyline; Antidepressive Agents; Clinical Trials as Topic; Combined Modality Therapy; De | 1994 |
Adverse drug reactions/interactions in maintenance therapy.
Topics: Antidepressive Agents; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Depressive Disorder; | 1993 |
A primary care perspective on management of acute and long-term depression.
Topics: Acute Disease; Adult; Aged; Depressive Disorder; Drug Administration Schedule; Drug Therapy, Combina | 1993 |
Management of recurrent depression.
Topics: 1-Naphthylamine; Antidepressive Agents; Chronic Disease; Combined Modality Therapy; Depressive Disor | 1993 |
Antidepressant discontinuation: a review of the literature.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder; Fluoxet | 1997 |
Sexual side effects of antidepressants.
Topics: Adult; Antidepressive Agents; Comorbidity; Depressive Disorder; Female; Fluoxetine; Humans; Incidenc | 2000 |
64 trials available for fluoxetine and Recrudescence
| Article | Year |
|---|---|
A Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at Ultrahigh Risk of Psychosis: The Staged Treatment in Early Psychosis (STEP) Sequential Multiple Assignment Randomized Trial.
Topics: Adolescent; Antipsychotic Agents; Female; Fluoxetine; Humans; Psychotic Disorders; Quality of Life; | 2023 |
Is sleep disturbance linked to short- and long-term outcomes following treatments for recurrent depression?
Topics: Adult; Antidepressive Agents; Cognitive Behavioral Therapy; Depressive Disorder, Major; Female; Fluo | 2020 |
Quality of life after response to acute-phase cognitive therapy for recurrent depression.
Topics: Adult; Cognitive Behavioral Therapy; Depression; Depressive Disorder, Major; Fluoxetine; Follow-Up S | 2021 |
Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration.
Topics: Accidental Falls; Affect; Aged; Cognition; Double-Blind Method; Fatigue; Female; Fluoxetine; Fractur | 2021 |
Time Course of Relapse Following Acute Treatment for Anorexia Nervosa.
Topics: Adolescent; Adult; Anorexia Nervosa; Cognitive Behavioral Therapy; Combined Modality Therapy; Female | 2021 |
Initial Steps to inform selection of continuation cognitive therapy or fluoxetine for higher risk responders to cognitive therapy for recurrent major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depressive Disorder, | 2017 |
Effect of fluoxetine on three-year recurrence in acute ischemic stroke: A randomized controlled clinical study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Pressure; Brain Ischemia; Female; Fluoxetine; Foll | 2018 |
A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRes
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Cost-Benefit Analysis; Depression; Double-Blind Meth | 2019 |
Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.
Topics: Adult; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; | 2014 |
Sequential treatment with fluoxetine and relapse--prevention CBT to improve outcomes in pediatric depression.
Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Maj | 2014 |
Stable remission and recovery after acute-phase cognitive therapy for recurrent major depressive disorder.
Topics: Acute Disease; Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depres | 2014 |
Predictors of longitudinal outcomes after unstable response to acute-phase cognitive therapy for major depressive disorder.
Topics: Adult; Age Factors; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral | 2015 |
Improved cognitive content endures for 2 years among unstable responders to acute-phase cognitive therapy for recurrent major depressive disorder.
Topics: Adult; Attitude; Cognitive Behavioral Therapy; Depressive Disorder, Major; Female; Fluoxetine; Follo | 2015 |
Assessing cognitive therapy skills comprehension, acquisition, and use by means of an independent observer version of the Skills of Cognitive Therapy (SoCT-IO).
Topics: Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Comprehension; Depression; D | 2016 |
Continued Effectiveness of Relapse Prevention Cognitive-Behavioral Therapy Following Fluoxetine Treatment in Youth With Major Depressive Disorder.
Topics: Adolescent; Child; Cognition; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Di | 2015 |
Quantifying and qualifying the preventive effects of acute-phase cognitive therapy: Pathways to personalizing care.
Topics: Acute Disease; Adult; Aged; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; | 2016 |
Longitudinal social-interpersonal functioning among higher-risk responders to acute-phase cognitive therapy for recurrent major depressive disorder.
Topics: Adult; Cognitive Behavioral Therapy; Depressive Disorder, Major; Female; Fluoxetine; Follow-Up Studi | 2016 |
Fluoxetine vs. placebo for the treatment of recurrent vasovagal syncope with anxiety sensitivity.
Topics: Adult; Anti-Anxiety Agents; Anxiety; Cardiovascular Agents; Female; Fluoxetine; Greece; Humans; Male | 2017 |
Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Fluoxeti | 2017 |
Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depress | 2008 |
A short duration of untreated illness (DUI) improves response outcomes in first-depressive episodes.
Topics: Adult; Citalopram; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disorders; Femal | 2010 |
Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Second-Generation; Bip | 2010 |
Recovery and recurrence following treatment for adolescent major depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit | 2011 |
Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse.
Topics: Acute Disease; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorde | 2011 |
Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality The | 2002 |
When should a trial of fluoxetine for major depression be declared failed?
Topics: Adolescent; Adult; Aged; Depressive Disorder; Disease Progression; Double-Blind Method; Drug Adminis | 2003 |
[Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment].
Topics: Antidepressive Agents, Second-Generation; Cohort Studies; Depression; Female; Fluoxetine; Follow-Up | 2003 |
Experimenter-defined quit dates for smoking cessation: adherence improves outcomes for women but not for men.
Topics: Adolescent; Adult; Aged; Behavior Therapy; Female; Fluoxetine; Humans; Male; Middle Aged; Patient Co | 2004 |
Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy.
Topics: Adult; Ambulatory Care; Depressive Disorder; Drug Administration Schedule; Female; Fluoxetine; Folic | 2004 |
Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study.
Topics: Administration, Oral; Adolescent; Child; Depressive Disorder; Double-Blind Method; Female; Fluoxetin | 2004 |
Control of urine marking by use of long-term treatment with fluoxetine or clomipramine in cats.
Topics: Administration, Oral; Animals; Behavior, Animal; Cat Diseases; Cats; Clomipramine; Drug Administrati | 2005 |
Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder.
Topics: Adult; Age of Onset; Anticonvulsants; Depressive Disorder, Major; Double-Blind Method; Drug Administ | 2005 |
Fluoxetine vs. propranolol in the treatment of vasovagal syncope: a prospective, randomized, placebo-controlled study.
Topics: Adrenergic beta-Antagonists; Adult; Attitude to Health; Double-Blind Method; Female; Fluoxetine; Hum | 2006 |
Extreme response style in recurrent and chronically depressed patients: change with antidepressant administration and stability during continuation treatment.
Topics: Acute Disease; Adult; Chronic Disease; Cognitive Behavioral Therapy; Depressive Disorder, Major; Dos | 2007 |
Moclobemide and fluoxetine in the prevention of relapses following acute treatment of depression.
Topics: Acute Disease; Adult; Antidepressive Agents; Benzamides; Depressive Disorder; Dose-Response Relation | 1995 |
Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose.
Topics: Adult; Ambulatory Care; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; | 1995 |
Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics.
Topics: Adult; Alcohol Drinking; Alcoholism; Combined Modality Therapy; Comorbidity; Depressive Disorder; Dr | 1995 |
Lack of efficacy of fluoxetine in recurrent brief depression and suicidal attempts.
Topics: Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug A | 1994 |
Childhood psychopathology retrospectively assessed among adults with early onset major depression.
Topics: 1-Naphthylamine; Adolescent; Adult; Anxiety Disorders; Child; Child Behavior Disorders; Comorbidity; | 1994 |
Treatment of recurrent unipolar depressions: psychological and biological aspects.
Topics: Depressive Disorder; Fluoxetine; Humans; Placebos; Recurrence | 1994 |
Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes?
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Appetite; Body Weight; Depressive Disor | 1996 |
Serotonergic drugs in trichotillomania: treatment results in 12 patients.
Topics: Adolescent; Adult; Age of Onset; Clomipramine; Female; Fluoxetine; Fluvoxamine; Humans; Male; Recurr | 1996 |
The effects of extended evaluation on depressive symptoms in children and adolescents.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Depression; Depressive Disorder; Double | 1996 |
Six month follow-up of early-onset chronic depression.
Topics: 1-Naphthylamine; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; | 1996 |
Fluoxetine discontinuation in elderly dysthymic patients.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Dose-Response Relationship, | 1997 |
Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo.
Topics: Adolescent; Adult; Aged; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; | 1998 |
Fluoxetine in child and adolescent depression: acute and maintenance treatment.
Topics: Acute Disease; Adolescent; Antidepressive Agents, Second-Generation; Anxiety; Chi-Square Distributio | 1998 |
Efficacy and safety of fluoxetine in treating bipolar II major depressive episode.
Topics: Adolescent; Adult; Age of Onset; Aged; Antidepressive Agents, Second-Generation; Bipolar Disorder; C | 1998 |
Weight suppression and weight rebound in ex-smokers treated with fluoxetine.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoxetine; Humans; Male; Midd | 1999 |
Weight suppression and weight rebound in ex-smokers treated with fluoxetine.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoxetine; Humans; Male; Midd | 1999 |
Weight suppression and weight rebound in ex-smokers treated with fluoxetine.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoxetine; Humans; Male; Midd | 1999 |
Weight suppression and weight rebound in ex-smokers treated with fluoxetine.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoxetine; Humans; Male; Midd | 1999 |
One year clinical and psychosocial outcomes of early-onset chronic depression.
Topics: Adult; Age Factors; Antidepressive Agents, Tricyclic; Chronic Disease; Depressive Disorder; Female; | 1999 |
Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action.
Topics: Adult; Aged; Amino Acids; Analysis of Variance; Antidepressive Agents, Second-Generation; Antidepres | 1999 |
Effects of prior fluoxetine treatment on EEG sleep in women with recurrent depression.
Topics: Adult; Combined Modality Therapy; Depressive Disorder; Electroencephalography; Female; Fluoxetine; H | 1999 |
Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group.
Topics: Adult; Antidepressive Agents, Second-Generation; Dose-Response Relationship, Drug; Female; Fluoxetin | 1999 |
Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Dou | 2000 |
Influence of panic-agoraphobic spectrum symptoms on treatment response in patients with recurrent major depression.
Topics: Adult; Agoraphobia; Ambulatory Care; Antidepressive Agents; Combined Modality Therapy; Comorbidity; | 2000 |
Fluoxetine for bulimia nervosa following poor response to psychotherapy.
Topics: Adult; Bulimia; Cognitive Behavioral Therapy; Drug Administration Schedule; Female; Fluoxetine; Huma | 2000 |
The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder.
Topics: Adolescent; Adult; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; F | 2000 |
Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Double-Blind Method; Female; Fluo | 2001 |
Coadministration of melatonin and fluoxetine does not improve the 3-month outcome following ECT.
Topics: Aged; Bipolar Disorder; Combined Modality Therapy; Depressive Disorder, Major; Dose-Response Relatio | 2001 |
Influences of gender and weight gain on short-term relapse to smoking in a cessation trial.
Topics: Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Dose-Response Relationship, Drug; Do | 2001 |
A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment.
Topics: Adolescent; Adult; Bulimia; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoxetin | 2002 |
Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus.
Topics: Aged; Female; Fluoxetine; Humans; Male; Paroxetine; Polycythemia Vera; Pruritus; Recurrence; Selecti | 2002 |
Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment.
Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedu | 2002 |
Fluoxetine in tricyclic refractory major depressive disorder.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Dose-Response Relationship, Drug; Doub | 1990 |
67 other studies available for fluoxetine and Recrudescence
| Article | Year |
|---|---|
The interaction between Environmental Enrichment and fluoxetine in inhibiting sucrose-seeking renewal in mice depend on social living condition.
Topics: Animals; Environment; Fluoxetine; Male; Mice; Mice, Inbred C57BL; Recurrence; Self Administration; S | 2022 |
Pica: obsessive-compulsive spectrum disorder, recurrent depression or eating disorder?
Topics: Adult; Anemia, Iron-Deficiency; Depression; Feeding and Eating Disorders; Female; Fluoxetine; Humans | 2020 |
Do Cognitive Therapy Skills Neutralize Lifetime Stress to Improve Treatment Outcomes in Recurrent Depression?
Topics: Cognitive Behavioral Therapy; Depression; Depressive Disorder, Major; Fluoxetine; Humans; Recurrence | 2020 |
Patients' comprehension and skill usage as a putative mediator of change or an engaged target in cognitive therapy: Preliminary findings.
Topics: Adult; Cognitive Behavioral Therapy; Comprehension; Depression; Depressive Disorder, Major; Female; | 2018 |
Do comorbid social and other anxiety disorders predict outcomes during and after cognitive therapy for depression?
Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Comorbidity; Depressi | 2019 |
Bupropion, a possible antidepressant without negative effects on alcohol relapse.
Topics: Alcohol Drinking; Alcoholism; Animals; Antidepressive Agents, Second-Generation; Bupropion; Dopamine | 2019 |
Could Treatment Matching Patients' Beliefs About Depression Improve Outcomes?
Topics: Adult; Chronic Disease; Cognitive Behavioral Therapy; Depression; Depressive Disorder, Major; Female | 2019 |
Cessation of fluoxetine treatment increases alcohol seeking during relapse and dysregulates endocannabinoid and glutamatergic signaling in the central amygdala.
Topics: Alcoholism; Animals; Central Amygdaloid Nucleus; Disease Models, Animal; Drug-Seeking Behavior; Endo | 2020 |
Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: outcome after long-term follow-up.
Topics: Adult; Citalopram; Cognitive Behavioral Therapy; Cohort Studies; Combined Modality Therapy; Depressi | 2015 |
One-Year Follow-up of Children and Adolescents with Major Depressive Disorder: Relationship between Clinical Variables and Abcb1 Gene Polymorphisms.
Topics: Adolescent; ATP Binding Cassette Transporter, Subfamily B, Member 1; Depressive Disorder, Major; Fem | 2016 |
Adult hippocampal neuroplasticity triggers susceptibility to recurrent depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depressive Disorder; Disease Models, Animal; Disea | 2017 |
Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder.
Topics: Adult; Affect; Anticonvulsants; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar | 2008 |
An angry bed partner.
Topics: Anger; Antidepressive Agents, Second-Generation; Bupropion; Coronary Artery Disease; Depressive Diso | 2009 |
Agomelatine: new drug. Adverse effects and no proven efficacy.
Topics: Acetamides; Animals; Antidepressive Agents; Bias; Carcinogens; Clinical Trials as Topic; Cyclohexano | 2009 |
Anxiety as a predictor of treatment outcome in children and adolescents with depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Anxiety Disorders; Child; Depressive Disorder, | 2010 |
Antidepressant use in bipolar disorder: continuing an age-old debate.
Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Evidence-Based Medicine; Fluoxetine; Hum | 2010 |
A rare cause of syncope: cough.
Topics: Antidepressive Agents, Second-Generation; Cough; Fluoxetine; Gastroesophageal Reflux; Humans; Male; | 2012 |
Anxiety- rather than depression-like behavior is associated with adult neurogenesis in a female mouse model of higher trait anxiety- and comorbid depression-like behavior.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Biomarkers; Dentate | 2012 |
Hypomania associated with adjunctive aripiprazole in an elder female with recurrent major depressive disorder: dose-related phenomenon?
Topics: Aripiprazole; Bipolar Disorder; Clonazepam; Depressive Disorder, Major; Dose-Response Relationship, | 2012 |
Repeated activation of mania by atypical antipsychotics in a patient.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Substitution; Drug Therapy, Combinatio | 2012 |
[The comparative study on the efficacy of the combination of serotonin reuptake inhibitor antidepressants and antipsychotics in the treatment of recurrent depressive disorders].
Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benz | 2012 |
The role of corticotropin-releasing factor in the median raphe nucleus in relapse to alcohol.
Topics: Alcoholism; Animals; Behavior, Animal; Choice Behavior; Corticotropin-Releasing Hormone; Disease Mod | 2002 |
Management of major depression during pregnancy.
Topics: Adult; Antidepressive Agents; Behavior Therapy; Depressive Disorder; Female; Fluoxetine; Humans; Pre | 2002 |
Fluoxetine in relapse prevention of PTSD.
Topics: Fluoxetine; Humans; Recurrence; Selective Serotonin Reuptake Inhibitors; Stress Disorders, Post-Trau | 2003 |
Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment.
Topics: Adult; Antidepressive Agents, Second-Generation; Drug Administration Schedule; Female; Fluoxetine; H | 2003 |
Long-term treatment of an addictive personality.
Topics: Adult; Antidepressive Agents, Second-Generation; Behavior, Addictive; Depressive Disorder; Diagnosis | 2003 |
Serotonin and stress: protective or malevolent actions in the biobehavioral response to repeated trauma?
Topics: Animals; Behavior; Fenclonine; Fluoxetine; Maze Learning; Memory; Psychomotor Performance; Rats; Rec | 2004 |
What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors?
Topics: Adult; Adverse Drug Reaction Reporting Systems; Data Interpretation, Statistical; Depressive Disorde | 2005 |
The resistance to depressive relapse in menopausal women undergoing tryptophan depletion: preliminary findings.
Topics: Adult; Affect; Cognition; Depressive Disorder, Major; Drug Therapy, Combination; Estradiol; Female; | 2007 |
Maintenance treatment with fluoxetine is necessary to sustain normal levels of synaptic markers in an experimental model of depression: correlation with behavioral response.
Topics: Animals; Antidepressive Agents, Second-Generation; Axons; Behavior, Animal; Biomarkers; Cytoskeleton | 2008 |
Concern over Prozac-induced tumor growth may dwindle following FDA study.
Topics: Amitriptyline; Animals; Depression; Fluoxetine; Humans; Loratadine; Neoplasms; Recurrence; United St | 1995 |
Attenuation of response to serotonin reuptake inhibitors.
Topics: 1-Naphthylamine; Adult; Depressive Disorder; Drug Therapy, Combination; Drug Tolerance; Female; Fluo | 1995 |
Fluoxetine-associated panic attacks.
Topics: Adult; Depressive Disorder; Female; Fluoxetine; Humans; Panic; Premenstrual Syndrome; Recurrence; Su | 1994 |
The use of serotonin reuptake inhibitors for the treatment of recurrent syncope due to carotid sinus hypersensitivity unresponsive to dual chamber cardiac pacing.
Topics: 1-Naphthylamine; Aged; Cardiac Pacing, Artificial; Carotid Sinus; Fluoxetine; Follow-Up Studies; Hea | 1994 |
Discontinuing obsessive-compulsive disorder medication with behavior therapy.
Topics: Adult; Behavior Therapy; Clomipramine; Combined Modality Therapy; Female; Fluoxetine; Follow-Up Stud | 1994 |
Adverse interaction of cyproheptadine with serotonergic antidepressants.
Topics: Acute Disease; Cyproheptadine; Depressive Disorder; Drug Interactions; Female; Fluoxetine; Humans; M | 1994 |
Titration of serotonin reuptake blockers.
Topics: Amantadine; Drug Administration Schedule; Fluoxetine; Humans; Mental Disorders; Recurrence; Selectiv | 1993 |
The benefits of clomipramine-fluoxetine combination in obsessive compulsive disorder.
Topics: Adult; Clomipramine; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combinatio | 1993 |
Recurrent hyponatremia associated with fluoxetine and paroxetine.
Topics: Aged; Depressive Disorder; Female; Fluoxetine; Humans; Hyponatremia; Inappropriate ADH Syndrome; Par | 1996 |
[Toxic tricyclic drug plasma level caused by fluoxetine].
Topics: Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressiv | 1995 |
Priapism associated with fluoxetine therapy: a case report.
Topics: Adult; Depressive Disorder; Fluoxetine; Humans; Male; Priapism; Recurrence | 1996 |
Depression as a dynamical disease.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Arousal; Brain; C | 1996 |
Drug craving and other negative reactions after abrupt substitution of nefazodone for other serotonergic agents.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Drug Administration Schedule; Female; Fluox | 1996 |
Two-year outcome of elderly patients with anxious depression.
Topics: Aged; Antidepressive Agents; Anxiety Disorders; Depressive Disorder; Dose-Response Relationship, Dru | 1997 |
Belinda's puzzle: assembling the pieces of an illness.
Topics: Adult; Depressive Disorder; Female; Fluoxetine; Humans; Recurrence | 1997 |
Psychiatrists' responses to failure of maintenance therapy with antidepressants.
Topics: 1-Naphthylamine; Adult; Antidepressive Agents; Attitude of Health Personnel; Depressive Disorder; Do | 1997 |
Rebound psychiatric and physical symptoms after gabapentin discontinuation.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Fluoxetin | 1998 |
[Choice of therapeutic tactics in treatment of endogenous depression by means of statusmetric expert system].
Topics: 1-Naphthylamine; Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder; Fluoxetine; F | 1997 |
[Effectiveness of fluoxetine (portal) in atypical depressions].
Topics: Adolescent; Adult; Chronic Disease; Depression; Female; Fluoxetine; Follow-Up Studies; Humans; Male; | 1998 |
Placebos and relapse in depression.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Fluoxetine; Humans; Placebo Effect; P | 1999 |
SSRI-induced reversal of levodopa benefit in two patients with dopa-responsive dystonia.
Topics: Adult; Antiparkinson Agents; Dystonia; Female; Fluoxetine; Humans; Levodopa; Recurrence; Selective S | 1999 |
Maintenance treatment for recurrent depression in late life. A four-year outcome study.
Topics: Aged; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder, Major; Drug Therapy, Co | 2000 |
Fluoxetine treatment in patients with recurrent brief depression.
Topics: Adult; Depressive Disorder; Female; Fluoxetine; Follow-Up Studies; Humans; Male; Middle Aged; Person | 2001 |
Long-term treatment of recurrent and chronic depression.
Topics: Antidepressive Agents; Chronic Disease; Clinical Trials as Topic; Cognitive Behavioral Therapy; Comb | 2001 |
Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression.
Topics: 1-Naphthylamine; Adult; Aged; Aged, 80 and over; Depressive Disorder; Drug Therapy, Combination; Fem | 1992 |
Possible clozapine exacerbation of bulimia nervosa.
Topics: Acute Disease; Adult; Bulimia; Clozapine; Dyskinesia, Drug-Induced; Female; Fluoxetine; Humans; Recu | 1992 |
Augmenting fluoxetine with dextroamphetamine to treat refractory depression.
Topics: Adult; Child of Impaired Parents; Depressive Disorder; Dextroamphetamine; Dose-Response Relationship | 1992 |
Fluoxetine, suicidal ideation, and aggressive behavior.
Topics: Aggression; Depressive Disorder; Female; Fluoxetine; Humans; Middle Aged; Recurrence; Social Isolati | 1992 |
Fluoxetine-induced anorexia in a bulimic patient.
Topics: Adult; Amenorrhea; Anorexia Nervosa; Bulimia; Female; Fluoxetine; Humans; Recurrence; Weight Gain | 1992 |
Fluoxetine and reactivation of the herpes simplex virus.
Topics: Adult; Depressive Disorder; Female; Fluoxetine; Herpes Simplex; Humans; Immunity, Cellular; Male; Mi | 1991 |
Does fluoxetine have a therapeutic window?
Topics: Depressive Disorder; Dose-Response Relationship, Drug; Fluoxetine; Humans; Male; Middle Aged; Recurr | 1991 |
Fluoxetine-lithium treatment for kleptomania.
Topics: Adult; Disruptive, Impulse Control, and Conduct Disorders; Drug Therapy, Combination; Female; Fluoxe | 1992 |
Reversal of antidepressant activity of fluoxetine by cyproheptadine in three patients.
Topics: Adult; Cyproheptadine; Depressive Disorder; Drug Interactions; Fluoxetine; Humans; Male; Middle Aged | 1991 |
Tourette syndrome and recurrent paraphilic masturbatory fantasy.
Topics: Adult; Fantasy; Fluoxetine; Humans; Male; Masturbation; Paraphilic Disorders; Recurrence; Tourette S | 1991 |
Fluoxetine and neuroleptic malignant syndrome.
Topics: Depressive Disorder; Drug Therapy, Combination; Fluoxetine; Humans; Male; Middle Aged; Neuroleptic M | 1990 |
Mania during fluoxetine treatment for recurrent depression.
Topics: Age Factors; Aged; Bipolar Disorder; Depressive Disorder; Fluoxetine; Humans; Male; Middle Aged; Psy | 1989 |
Treatment of a refractory depression with a combination of fluoxetine and d-amphetamine.
Topics: Adult; Depressive Disorder; Dextroamphetamine; Drug Combinations; Fluoxetine; Humans; Male; Recurren | 1989 |